Activin-A, Growth Differentiation Factor-11 and Transforming Growth Factor-β as predictive biomarkers for platinum chemotherapy in advanced non-small cell lung cancer

AIHW. Cancer Data in Australia. 2020. Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 13, 239, 10.1016/S1470-2045(11)70393-X Solomon, 2014, First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer, New England Journal of Medicine, 371, 2167, 10.1056/NEJMoa1408440 Shaw, 2014, Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer, New England Journal of Medicine, 371, 1963, 10.1056/NEJMoa1406766 Reck, 2016, Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer, New England Journal of Medicine, 375, 1823, 10.1056/NEJMoa1606774 Socinski, 2018, Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC, New England Journal of Medicine, 378, 2288, 10.1056/NEJMoa1716948 Gandhi, 2018, Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer, New England Journal of Medicine, 378, 2078, 10.1056/NEJMoa1801005 Rajeswaran, 2008, Lung Cancer, 59, 1, 10.1016/j.lungcan.2007.07.012 Pignon, 2008, Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group, Journal of Clinical Oncology, 26, 3552, 10.1200/JCO.2007.13.9030 Albain, 2002, Concurrent Cisplatin, Etoposide, and Chest Radiotherapy in Pathologic Stage IIIB Non–Small-Cell Lung Cancer: A Southwest Oncology Group Phase II Study, SWOG 9019, Journal of Clinical Oncology, 20, 3454, 10.1200/JCO.2002.03.055 Kelland, 2000, Preclinical Perspectives on Platinum Resistance, Drugs, 59, 1, 10.2165/00003495-200059004-00001 Jiang, 2012, ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis, Molecular Biology Reports, 39, 6933, 10.1007/s11033-012-1520-4 Novello, 2022, Annals of Oncology, 33, 57, 10.1016/j.annonc.2021.09.017 Wu, 2014, Nuclear survivin expression: a prognostic factor for the response to taxane–platinum chemotherapy in patients with advanced non-small cell lung cancer, Medical Oncology, 31, 79, 10.1007/s12032-014-0079-4 Ferrer, 2005, FANCD2 Expression in Advanced Non–Small-Cell Lung Cancer and Response to Platinum-Based Chemotherapy, Clinical Lung Cancer, 6, 250, 10.3816/CLC.2005.n.005 Marini, 2018, Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy, Science Translational Medicine, 10, eaat3504, 10.1126/scitranslmed.aat3504 Detre, 1995, A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas, Journal of Clinical Pathology, 48, 876, 10.1136/jcp.48.9.876 Gao, 2014, Expression of TGFβ-1 and EHD1 correlated with survival of non-small cell lung cancer, Tumour Biol, 35, 9371, 10.1007/s13277-014-2164-x Takanami, 1994, Transforming growth factor beta 1 as a prognostic factor in pulmonary adenocarcinoma, J Clin Pathol, 47, 1098, 10.1136/jcp.47.12.1098 de Kretser, 2012, The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair, Molecular and Cellular Endocrinology, 359, 101, 10.1016/j.mce.2011.10.009 Loumaye, 2015, Role of Activin A and Myostatin in Human Cancer Cachexia, The Journal of Clinical Endocrinology & Metabolism, 100, 2030, 10.1210/jc.2014-4318 Togashi, 2015, Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer, Cancer Letters, 356, 819, 10.1016/j.canlet.2014.10.037 Wang, 2015, Activin A expression in esophageal carcinoma and its association with tumor aggressiveness and differentiation, Oncol Lett, 10, 143, 10.3892/ol.2015.3248 Donovan, 2017, Paracrine Activin-A signaling promotes melanoma growth and metastasis through immune evasion, bioRxiv Seder, 2009, Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma, Neoplasia, 11, 388, 10.1593/neo.81582 Wamsley, 2015, Activin upregulation by NF-κB is required to maintain mesenchymal features of cancer stem-like cells in non-small cell lung cancer, Cancer Res, 75, 426, 10.1158/0008-5472.CAN-13-2702 Paajanen, 2020, Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy, Clin Lung Cancer, 21, e142, 10.1016/j.cllc.2019.10.013 Hoda, 2016, Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma – A multi-institutional study, European Journal of Cancer, 63, 64, 10.1016/j.ejca.2016.04.018 Barany, 2021, Clinical relevance of circulating activin A and follistatin in small cell lung cancer, Lung Cancer, 161, 128, 10.1016/j.lungcan.2021.09.008